BCAX
BCAX clinical trials: Bicara Therapeutics Inc.
Every trial on ClinicalTrials.gov where Bicara Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 6
- Trials linked
- 3
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BCAX on the catalyst calendar · BCAX registry changes
- Primary completion Apr 2028Sponsor estimatePhase 2/Phase 3NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCBicara Therapeutics · Metastatic Head and Neck Squamous Cell CarcinomaRecruitingBCAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 2NCT07807163A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCBicara Therapeutics · Metastatic Head and Neck Squamous Cell CarcinomaRecruitingBCAXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2027Sponsor estimatePhase 1NCT04429542Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsBicara Therapeutics · Head and Neck Squamous Cell CarcinomaRecruitingBCAXLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2029Sponsor estimatePhase 1/Phase 2NCT07552558Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Washington University School of Medicine · Head and Neck Squamous Cell CarcinomaNot yet recruitingBCAXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2030Sponsor estimatePhase 2NCT07529873Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaGroupe Oncologie Radiotherapie Tete et Cou · Squamous Cell Carcinoma of Head and Neck (SCCHN)RecruitingBCAXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2028Sponsor estimatePhase 2NCT07465276Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCDana-Farber Cancer Institute · Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingBCAXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner